This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Drug buyer accuses Celgene of illegally maintaining Thalomid, Revlimid monopoly

( November 7, 2014, 12:00 GMT | Official Statement) -- MLex Summary: Drug company Celgene has used safety restrictions on the distribution of the drugs Thalomid and Revlimid to stop generic rivals from making their own versions, a health fund said in an antitrust class action complaint filed in the US District Court for the District of New Jersey. Celgene has also obtained fraudulent patents and filed sham litigation to keep its monopoly on the costly drugs, the International Union of Bricklayers and Allied Craft Workers Local 1 Health Fund said.See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections